Arina Martynchyk
YOU?
Author Swipe
View article: T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial Open
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffecti…
View article: 14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0
14 | PERFORMANCE OF BASELINE AND END‐OF‐TREATMENT FDG‐PET RADIOMICS IN PATIENTS WITH PERIPHERAL T‐CELL LYMPHOMA: DATA FROM INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0 Open
View article: 626 | AUSTRALIAN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA FREQUENTLY FAIL ELIGIBILITY CRITERIA FOR LANDMARK AND REGISTRATION CLINICAL TRIALS
626 | AUSTRALIAN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA FREQUENTLY FAIL ELIGIBILITY CRITERIA FOR LANDMARK AND REGISTRATION CLINICAL TRIALS Open
View article: Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report Open
Background Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real‐world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and infor…
View article: Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI
Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI Open
Background Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma restricted to the CNS in which outcomes cannot be reliably predicted. The International PCNSL Collaborative Group developed standardized response assessme…
View article: Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study
Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study Open
Background There is no strong evidence supporting brentuximab vedotine (BV) efficacy as a salvage regimen for relapsed/refractory Hodgkin’s lymphoma (R/R HL) patients before autologous hematopoietic cell transplantation (auto‐HCT). Methods…
View article: Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more
Learnings from phosphatidylinositol 3‐kinase inhibitors in lymphoma—Moving to a model where less can be more Open
The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one‐size‐fits‐all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K …
View article: Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019–2021
Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019–2021 Open
Summary We report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019–2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130 (23.1%) of diffuse large B‐cell lymphoma (DLBCL), 28 (5%) of follicular lymphoma (FL)…
View article: Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma Open
Classical Hodgkin lymphoma (cHL) accounts for 0.4% of all new cancer cases globally. Despite high cure rates with standard treatment, approximately 15% of patients still experience relapsed or refractory (RR) disease, and many of these eve…
View article: Interim 3‐Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL)
Interim 3‐Dimensional volumetric response (3DVR) is associated with better overall survival of patients (pts) with primary central nervous system lymphoma (PCNSL) Open
Introduction: PCNSL outcome risk determination is currently not standardized and the prognostic role of 2-Dimensional (2D) response assessment is controversial (van de Meulen 2021). 3DVR; defined as a reduction of at least 65%, is predicti…
View article: Comparison of the efficiency of peripheral blood stem cell apheresis on the blood cell separators
Comparison of the efficiency of peripheral blood stem cell apheresis on the blood cell separators Open
The CEC for each device was within the generally accepted limits of 30-50%, and did not differ significantly. Nevertheless, using of the Amicus BCS allowed to collect lower volumes of the product, maintaining other characteristics of the p…
View article: Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification
Distribution of lymphoma subtypes in Ukraine according to the WHO 2016 classification Open
The Ukrainian Lymphoma Registry (ULR) was established in 2019 with the aim of monitoring the quality of diagnosis, staging, and treatment of lymphoma in Ukraine. Between September 2019 and October 2021, 546 patients with newly diagnosed ly…
View article: PB1812 PHARMACO‐ECONOMY ANALYSIS OF THE THREATMENT WITH R‐DA‐EPOCH, R‐CHOP, AND CHOP‐LIKE REGIMENS IN HIGH‐RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (UKRAINIAN MULTICENTER STUDY)
PB1812 PHARMACO‐ECONOMY ANALYSIS OF THE THREATMENT WITH R‐DA‐EPOCH, R‐CHOP, AND CHOP‐LIKE REGIMENS IN HIGH‐RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA (UKRAINIAN MULTICENTER STUDY) Open
Background: Diffuse large B‐cell lymphoma (DLBCL) is the most spread subtype of NHL. Outcomes of standard treatment in high‐risk patients are poor, especially in LMIC with limited access to expensive drugs and 2 nd line treatment. Aims: We…
View article: MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis
MAPK/ERK signal pathway alterations in patients with Langerhans Cell Histiocytosis Open
BRAF and NRAS mutations in LCH suggest a possibility of the disease being driven by the activation of the MAPK/ERK pathway. These oncogenic mutations provide new opportunities in understanding LCH pathogenesis and may be a potential target…
View article: PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
PROGNOSTIC VALUE OF IMMUNOHISTOCHEMICAL MARKERS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA Open
Diffuse large B-cell lymphoma (DLBCL) is a potentially curable disease, but standard treatment is not effective enough for all patients. That is why so important to identify high risk patients who need more aggressive therapy at the time o…
View article: R-da-EPOCH vs R-CHOP in patients with primary mediastinal large B-cell lymphoma: Results of randomised (prospective) multicenter study
R-da-EPOCH vs R-CHOP in patients with primary mediastinal large B-cell lymphoma: Results of randomised (prospective) multicenter study Open
View article: The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma
The predictive value of immunohistochemical expression of Bcl-2, Bcl-6, MUM1, CD10 and CD30 in patients with diffuse large cell lymphoma Open